Parkinson's Disease: Microbiome

The gut microbiota shares a symbiotic relationship with the human host. Dysbiosis is linked with several neurological pathologies including Parkinson’s disease (PD). Here is the latest research on the modulation of PD by the gut microbiota.

October 19, 2020

A review on preventive role of ketogenic diet (KD) in CNS disorders from the gut microbiota perspective

Reviews in the Neurosciences
Kajal RawatLekha Saha
January 6, 2021
Comment / Editorial
Open Access

Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"

Movement Disorders : Official Journal of the Movement Disorder Society
Xi Zhang
January 8, 2021
Open Access

Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease

Peipei LiViviane Labrie
August 28, 2020

Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease

Brain : a Journal of Neurology
Yiwei QianQin Xiao
December 31, 2020
Open Access

Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease

Tennekoon B KarunaratneAmol Sharma
October 14, 2020
Open Access

Using data science for medical decision making case: role of gut microbiome in multiple sclerosis

BMC Medical Informatics and Decision Making
Jasminka Hasic Telalovic, Azra Music
November 10, 2020

The Gut Mycobiome in Parkinson's Disease

Journal of Parkinson's Disease
Mihai S CirsteaSilke Appel-Cresswell
September 18, 2020

Gut microbiota dynamics in Parkinsonian mice

ACS Chemical Neuroscience
Emily KlannVinata Vedam-Mai
December 24, 2020
Open Access

Overexpression of human alpha-synuclein leads to dysregulated microbiome and metabolites with ageing in a rat model of Parkinson disease

BioRxiv : the Preprint Server for Biology
Yogesh SinghNicolas Casadei
January 11, 2021
Open Access

The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease

Journal of Neuroinflammation
Zach DwyerShawn Hayley
November 10, 2020

Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment.

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Magdalena KoszewiczGjumrakch Aliev
October 2, 2020
Open Access

DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs).

Scientific Reports
Yogesh SinghOlaf Riess
December 5, 2020
Open Access

Gut microbial ecosystem in Parkinson's disease: New clinico-biological insights from multi-omics

Annals of Neurology
Ai Huey TanAnthony E Lang
October 22, 2020

The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study

Future Microbiology
Federica Del ChiericoFabrizio Stocchi
October 21, 2020
Open Access

Gut bacterial deamination of residual levodopa medication for Parkinson's disease

BMC Biology
Sebastiaan P van KesselSahar El Aidy
December 29, 2020
Comment / Editorial
Open Access

Editorial: Role of Diet, Physical Activity and Immune System in Parkinson's Disease

Frontiers in Neurology
Giovanni AlbaniAli Keshavarzian
January 9, 2021

Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications

Neuroscience Research
Linchi Rani, Amal Chandra Mondal
January 3, 2021

Polydopamine-based nanomaterials and their potentials in advanced drug delivery and therapy

Colloids and Surfaces. B, Biointerfaces
Hanmei LiQiang Peng

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved